Biomarin Pharmaceutical Inc (BMRN) — Capital Reinvestment Ratio
Biomarin Pharmaceutical Inc (BMRN) has a Capital Reinvestment Ratio of 0.17x as of June 2026, meaning it reinvests 0% of its operating cash flow ($168.11 Million) in capital expenditures ($28.82 Million). Check tangible equity quality of Biomarin Pharmaceutical Inc to evaluate the tangible quality of the company's equity base.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Biomarin Pharmaceutical Inc Capital Reinvestment Ratio (2009–2025)
This chart tracks Biomarin Pharmaceutical Inc's Capital Reinvestment Ratio across 12 annual periods. For the full cash flow conversion analysis, see BMRN cash flow metrics.
Annual Capital Reinvestment Ratio for Biomarin Pharmaceutical Inc (2009–2025)
Year-by-year Capital Reinvestment Ratio for Biomarin Pharmaceutical Inc from 2009 to 2025. See BMRN free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
| Year | Reinvestment Ratio | Operating CF (USD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.12x | $827.99 Million | $103.04 Million | ▼ -26.8% |
| 2024 | 0.17x | $572.84 Million | $97.42 Million | ▼ -74.8% |
| 2023 | 0.68x | $159.26 Million | $107.61 Million | ▼ -1.7% |
| 2022 | 0.69x | $175.90 Million | $120.96 Million | ▲ +75.6% |
| 2021 | 0.39x | $304.54 Million | $119.22 Million | ▼ -75.7% |
| 2020 | 1.61x | $85.36 Million | $137.52 Million | ▼ -46.4% |
| 2019 | 3.00x | $48.26 Million | $145.03 Million | ▼ -58.0% |
| 2018 | 7.16x | $20.21 Million | $144.62 Million | ▲ +182.7% |
| 2012 | 2.53x | $17.61 Million | $44.57 Million | ▼ -69.2% |
| 2011 | 8.22x | $18.75 Million | $154.22 Million | ▲ +211.7% |
| 2010 | 2.64x | $18.75 Million | $49.46 Million | ▲ +157.8% |
| 2009 | 1.02x | $87.73 Million | $89.80 Million | — |